On Tuesday, The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
Japan is the second major market in which Kisunla has been approved for use.
Also Read: Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules.
In Japan, by 2030, the number of patients with dementia is estimated to be more than 5 million, and Alzheimer’s is the most common ...
